News OWC Pharmaceutical Research Corp. (OTC
Post# of 15624
(Total Views: 610)
Posted On: 08/01/2018 9:18:58 AM
News
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study"
to determine the safety and tolerability of topical ointment containing medical grade cannabis in healthy volunteers. On June 28, 2018 , the Company announced that it had successfully completed the initial stage of this trial, which comprised the single dosing of healthy volunteers. The final stage of the trial comprises the twice daily dosing of healthy volunteers for 6 weeks. The study is being performed by Professor Aviv Barzilai , Director of the Department of Dermatology at Chaim Sheba Medical Center . Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated medical centers in the Middle East .
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Mr. Mordechai Bignitz , the Chief Executive Officer of OWC commented, "We mentioned in our recent letter to shareholders that we were waiting for licenses in order to initiate this trial. This approval has now been obtained and we will immediately initiate clinical testing. Validation of safe and efficacious therapeutics is key to our mission and we aim to progress our studies as rapidly as possible, adhering to best clinical practices."
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study"
to determine the safety and tolerability of topical ointment containing medical grade cannabis in healthy volunteers. On June 28, 2018 , the Company announced that it had successfully completed the initial stage of this trial, which comprised the single dosing of healthy volunteers. The final stage of the trial comprises the twice daily dosing of healthy volunteers for 6 weeks. The study is being performed by Professor Aviv Barzilai , Director of the Department of Dermatology at Chaim Sheba Medical Center . Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated medical centers in the Middle East . (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Mr. Mordechai Bignitz , the Chief Executive Officer of OWC commented, "We mentioned in our recent letter to shareholders that we were waiting for licenses in order to initiate this trial. This approval has now been obtained and we will immediately initiate clinical testing. Validation of safe and efficacious therapeutics is key to our mission and we aim to progress our studies as rapidly as possible, adhering to best clinical practices."
(0)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼